qlf31907
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 6, 2021 (NCT05150405)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06394713 | Phase 1/Phase 2 (Phase 2) | Jun 15, 2024 | Qilu Pharmaceutical Co., Ltd. |
| NCT05823246 | Phase 2 | Apr 24, 2023 | Qilu Pharmaceutical Co., Ltd. |
| NCT05150405 | Phase 1 | Sep 6, 2021 | Qilu Pharmaceutical Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 2 | 2021 |
1 organizations
Page 1 / 1